ANIP — Q2 2026 Financial Report Analysis

Cortrophin Gel drives a 26% revenue jump, but a one-time licensing deal and a guidance trim matter just as much

ANI Pharmaceuticals makes three kinds of medicines: a "Rare Disease" business built around Purified Cortrophin Gel (an injectable hormone therapy, ACTH, used for flares of conditions such as kidney, nerve, eye, lung and joint diseases) and the eye implant ILUVIEN; a generic-drug business; and a smaller group of older branded drugs. In the second quarter of 2026 (April–June), total net revenue rose 25.9% to $266.0 million. Cortrophin Gel alone grew 43.5% to $117.1 million, and GAAP net income nearly tripled to $24.7 million, or $1.05 per diluted share, from $8.1 million ($0.36) available to common shareholders a year earlier.

Two things sit behind those headlines. First, $17.7 million of the quarter's revenue came from a licensing deal with Harmony Biosciences that did not exist last year, and part of it is one-time. Second, management kept its full-year revenue target but cut its Cortrophin Gel forecast to $520–$540 million from $540–$575 million. The rest of the company now has to cover that shortfall.

At a glance

• Cortrophin Gel $117.1M (+43.5%): the main product, up from $75.1 million in Q1. ANI credits volume growth in its existing specialties (nephrology, neurology, ophthalmology, pulmonology, rheumatology). The new gout sales push only became fully operational at the end of June, so it did not drive this quarter.
• Revenue growth of 17.5% without the Harmony money: taking out the $17.7 million of new Harmony licensing revenue, revenue was $248.3 million. That is still solid growth, but well below the 25.9% headline.
• Operating cash flow of $115.0M in H1, about 2.1x net income: first-half operating cash flow (cash actually brought in by running the business) was about double reported profit, and receivables fell slightly since December even as sales rose. Reported earnings are turning into cash.

Key figures

Operating margin is the share of revenue left after running the business, before interest and tax. ANI reports cost of sales excluding depreciation and amortization, so its "gross margin" is higher than it would be if those costs were included.

What drove the quarter

Rare Disease (+30.7% to $135.8M). Cortrophin Gel growth was "driven primarily by increased volume," the 10-Q says. For the first half the filing adds "overall ACTH market growth and market share gains." ANI's 2026 strategy is a new sales force that calls on podiatrists and primary-care doctors for acute gout flares. Gout is a use that is unique to Cortrophin among ACTH drugs, and ANI puts the addressable market at about 285,000 patients. That team was "fully operational as of the end of June," so most of its effect is still ahead. Early signals in the release are activity measures, not revenue: over 95% of reps have generated multiple new patient cases, and over a third of prescribers have started two or more. ILUVIEN fell 16.1% to $18.7 million, which ANI attributes to the timing of international shipments. For the half year it was down only 1.2%.

Generics (+9.7% to $99.1M). A partnered generic launched in Q3 2025 and new launches drove the increase. ANI has launched 12 generics so far this year and is aiming for at least 15. Over the half year, Vancomycin and MAS ER grew, while Prucalopride sales declined.

Brands (−10.5% to $11.8M). ANI describes this as "a normalization in demand for certain products." The half-year decline is steeper: −37.0%, to $24.1 million.

Harmony licensing ($17.7M, new). In January, ANI's Novitium subsidiary licensed intellectual property to Harmony Biosciences for a new formulation of pitolisant. Pitolisant is Harmony's sleep-disorder drug, and the new formulation targets other central-nervous-system uses. This quarter's $17.7 million combines $9.7 million of royalties (low-single-digit royalties on Harmony's pitolisant sales, which keep coming) with $8.0 million recognized toward $10.0 million of development milestones. ANI expects to book the last $2.0 million of those milestones in Q3, after which they end. Q1 also included a $15.0 million upfront fee.

Costs. Gross margin fell to 62.4% from 64.7%. The reasons given are more sales of products on which ANI owes royalties (Cortrophin Gel and the partnered generic) and the loss of last year's Prucalopride sales. The Harmony revenue partly offset this. SG&A (selling, general and administrative costs) rose 12.1% to $91.7 million because of the gout sales-force build-out, partly offset by lower legal costs. R&D fell 10.8% to $14.7 million, which ANI puts down to project timing.

What the headline numbers hide

• Harmony revenue lifted the profit jump more than it lifted revenue. The $17.7 million equals about 44% of the quarter's $40.5 million operating income. The filing says the Harmony revenue "tempered" the decline in gross margin, which points to little direct cost. If it had none, the rest of the business would have earned roughly $22.7 million of operating income, an operating margin of about 9%. That is still better than last year's 6.6%, but far from the reported 15.2%. The $8.0 million milestone portion won't repeat after Q3.
• Last year's quarter was weighed down by one-off costs. Q2 2025 included $5.2 million of litigation expense, a $1.3 million charge for contingent consideration (payments owed on past acquisitions, revalued each quarter) and $0.8 million of deal costs. In Q2 2026 those lines were $0.7 million of litigation expense, a $0.6 million contingent-consideration gain and nearly nothing for deals. Depreciation and amortization also fell to $19.6 million from $23.3 million. Together these explain part of the near-tripling in GAAP profit.
• A higher tax rate partly offset the gains. Pre-tax income rose 252% to $37.1 million, but net income rose "only" 189%. The effective tax rate was 33.4%, against 18.8% a year ago, when favorable adjustments on foreign tax returns lowered the bill. Lower interest expense helped a little: $3.6 million, down from $5.4 million.
• Share count dilution, not buybacks. Diluted shares rose 7.9% to 21.9 million, so EPS growth lags net-income growth on a per-share basis. A $100 million buyback was authorized on May 8. The only treasury-stock purchases in the half-year cash flow, however, are $20.6 million of shares withheld when restricted stock vested, which is not open-market buying.
• The adjusted-vs-GAAP gap is large and mostly non-cash. Adjusted EPS of $2.21 is more than double GAAP's $1.05. The main add-backs are $19.6 million of depreciation and amortization and $11.4 million of stock-based compensation, less the tax effect. Excluding amortization of acquired products is standard for the sector. Excluding stock compensation removes a real, recurring cost.
• Cash and working capital look clean. First-half operating cash flow of $115.0 million compares with net income of $54.2 million. Receivables were $274.5 million against $281.1 million at year-end, and inventory was flat at $143.1 million. ANI ended June with $360.2 million of cash and $620.9 million of debt principal (including convertible notes).

Takeaway: The core growth is real: Cortrophin Gel +43.5%, generics +9.7%, and cash flow well above earnings. But roughly 44% of operating income came from Harmony licensing revenue, part of which ends next quarter. Meanwhile, management trimmed its Cortrophin forecast while holding the company total. The second half now depends on the new gout sales force producing a much larger Cortrophin quarter than anything ANI has reported so far.

Guidance and what to watch

ANI reaffirmed its full-year 2026 targets: net revenue of $1,080–$1,140 million (+22–29%), adjusted EBITDA of $285–$300 million and adjusted EPS of $9.19–$9.69. The ILUVIEN forecast is unchanged at $78–$83 million. The one change is Cortrophin Gel, now $520–$540 million (+50–55%), down from $540–$575 million.

The arithmetic is demanding. After $192.2 million in the first half, Cortrophin needs $328–$348 million in the second half, or about $164–$174 million a quarter. That is 40–49% above Q2's record $117.1 million. For the whole company, the guidance implies second-half revenue of $576.5–$636.5 million, against $503.5 million in the first half. It also implies second-half adjusted EBITDA of $150–$165 million, against $134.6 million in the first half. Management says new Cortrophin cases hit a record in July, and it calls the gout metrics "very positive." The filing does not yet show either in revenue.

What to watch in Q3 (expected early November):

1. Cortrophin Gel revenue against a run-rate of about $165 million a quarter. A Q3 figure well short of that would make the reaffirmed company-wide guidance hard to reach without another cut.
2. Rare Disease margins as the gout sales force runs a full quarter. SG&A grew 12.1% this quarter with the team only partly staffed. The question is whether Cortrophin volume outgrows that cost base once the Harmony milestone revenue stops after Q3.

Figures are from ANI's Form 10-Q for the quarter ended June 30, 2026, and its Q2 2026 earnings release (Exhibit 99.1 to the Form 8-K filed August 7, 2026).